Low incidence of hyperacute graft-versus-host disease (GVHD) with effective GVHD prophylaxis based on anti-thymocyte globulin - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35245388/
doi: 10.1111/bjh.18099. Online ahead of print. 1 APHP, Hôpital Saint Antoine, Service d'Hématologie Clinique et de Thérapie cellulaire, Paris, France. 2 Clinical Hematology and Bone Marrow Transplant Centre, S. Maria della Misericordia Hospital, University of Udine, Udine, Italy. 3 INSERM, Centre de Recherche Saint-Antoine (CRSA), Sorbonne Université, Paris, France. doi: 10.1111/bjh.18099.
Conclusion: Overall, development of new strategies such as RTC and generalisation of in vivo T-cell depletion with ATG and/or PTCy, translate into a decreased incidence of haGVHD. Furthermore, despite a higher incidence of cGVHD in patients with haGVHD compared to aGVHD after day 14, NRM and OS were similar. This suggests that patients with haGVHD should no longer be excluded from clinical trials investigating new agents for aGVHD.9